Orion Investment Co Buys 675 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Orion Investment Co increased its stake in Regeneron Pharmaceuticals by 2.3%, owning 30,561 shares valued at approximately $19.4 million, making it the second largest holding in their portfolio.
• Regeneron Pharmaceuticals reported earnings per share of $12.89 for the last quarter, significantly surpassing analysts' expectations of $8.43, with revenue increasing 3.6% year-over-year.
• The company announced a quarterly dividend of $0.88 per share, resulting in a 0.6% dividend yield and reflecting a payout ratio of 8.87%.

Orion Investment Co grew its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 2.3% during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 30,561 shares of the biopharmaceutical company's stock after purchasing an additional 675 shares during the quarter. Regeneron Pharmaceuticals makes up approximately 8.0% of Orion Investment Co's holdings, making the stock its 2nd biggest holding. Orion Investment Co's holdings in Regeneron Pharmaceuticals were worth $19,383,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. GAMMA Investing LLC grew its position in shares of Regeneron Pharmaceuticals by 89,825.0% during the 1st quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock valued at $517,291,000 after buying an additional 814,713 shares during the last quarter. Nuveen LLC bought a new position in Regeneron Pharmaceuticals in the 1st quarter worth about $343,764,000. Pacer Advisors Inc. grew its position in Regeneron Pharmaceuticals by 2,296.9% in the 1st quarter. Pacer Advisors Inc. now owns 407,370 shares of the biopharmaceutical company's stock worth $258,366,000 after purchasing an additional 390,374 shares during the last quarter. Assenagon Asset Management S.A. grew its position in Regeneron Pharmaceuticals by 171.0% in the 1st quarter. Assenagon Asset Management S.A. now owns 481,389 shares of the biopharmaceutical company's stock worth $305,311,000 after purchasing an additional 303,785 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Regeneron Pharmaceuticals by 30.1% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 982,064 shares of the biopharmaceutical company's stock worth $699,554,000 after purchasing an additional 226,952 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company's stock.

Regeneron Pharmaceuticals Price Performance

REGN stock traded up $1.09 on Friday, hitting $580.70. 574,305 shares of the company's stock traded hands, compared to its average volume of 1,042,369. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $1,210.97. The stock has a market cap of $61.55 billion, a price-to-earnings ratio of 14.63, a P/E/G ratio of 1.93 and a beta of 0.33. The stock has a fifty day moving average of $557.26 and a 200-day moving average of $587.56. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, beating the consensus estimate of $8.43 by $4.46. The business had revenue of $3.68 billion during the quarter, compared to the consensus estimate of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The firm's quarterly revenue was up 3.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $11.56 EPS. On average, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Monday, August 18th will be given a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Monday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio is 8.87%.

Analysts Set New Price Targets

Several research firms have commented on REGN. Guggenheim upped their target price on shares of Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the stock a "buy" rating in a research report on Friday, August 1st. Truist Financial reduced their price target on shares of Regeneron Pharmaceuticals from $940.00 to $812.00 and set a "buy" rating for the company in a research note on Monday, August 11th. Royal Bank Of Canada upped their price target on shares of Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the stock a "sector perform" rating in a research note on Monday, August 4th. Rothschild & Co Redburn began coverage on shares of Regeneron Pharmaceuticals in a research note on Thursday, August 14th. They issued a "buy" rating and a $890.00 price target for the company. Finally, JPMorgan Chase & Co. reduced their price target on shares of Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating for the company in a research note on Monday, June 9th. Three analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $817.67.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.